Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 4

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 4
---
     |  11 |
| LEGAL MATTERS                                        |     |  14 |
| EXPERTS                                              |     |  14 |
| WHERE YOU CAN FIND ADDITIONAL INFORMATION            |     |  14 |
| INFORMATION INCORPORATED BY REFERENCE                |     |  14 |

You should rely only on the information provided in this prospectus, as well as the information incorporated by reference to exhibits to the registration statement of which this prospectus forms a part and any applicable prospectus supplement or amendment. Neither we nor the selling stockholders have authorized anyone to provide you with different information. Neither we nor the selling stockholders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents filed as exhibits to the registration statement of which this prospectus forms a part, our business, financial condition, results of operations and prospects may have changed. i

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”) using a “shelf”
registration process. Under this shelf registration process, the selling stockholders identified in this prospectus under the section entitled “Selling Stockholders,” may use the shelf registration statement to offer and resell, from time
to time, up to an aggregate of 1,565,044,860 shares of our common stock through any means described in the section entitled “Plan of Distribution”.

A prospectus supplement may also add, update or change information included in this prospectus. Any statement contained in this prospectus will be deemed to
be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus
only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. You should rely only on the information contained in this prospectus, any applicable prospectus supplement or any related free writing
prospectus, including any information incorporated by reference. See “Where You Can Find More Information” and “Information Incorporated by Reference.”

We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale